Conference Proceedings
LONG-TERM SURVIVAL IN WOMEN WITH HIGH-GRADE SEROUS OVARIAN CANCER: INTERPLAY BETWEEN RB1 AND BRCA1/2
FAM Saner, DW Garsed, JA Beach, A Pandey, S Fereday, K Alsop, MCA Wouters, N Traficante, CL Pearce, MC Pike, A de Fazio, SJ Ramus, M Kobel, EL Goode, BH Nelson, DDL Bowtell
International Journal of Gynecological Cancer | BMJ PUBLISHING GROUP | Published : 2019
Grants
Awarded by US Congressionally Directed Ovarian Cancer Research Program
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Funding Acknowledgements
F.A.M.S is supported by a Swiss National Foundation Early Postdoc Mobility Fellowship, a Swiss Cancer Research Foundation grant and the Prof. Dr. Max Cloetta foundation. D.W.G. is supported by U.S. Army Medical Research and Materiel Command grant. AOCS receives funding support from Astra Zeneca and Ovarian Cancer Australia. C.L.P. and M.C.P. acknowledge support from the US Congressionally Directed Ovarian Cancer Research Program administered by the US Army Medical research and Materiel Command, grant number W81XWH-16-2-0010. D.D.L.B. is supported by U.S. Army Medical Research and Materiel Command grant, by the National Health and Medical Research Council of Australia (NHMRC) grants APP1092856 and APP1117044, the US National Cancer Institute U54 program, and receives research funding from Astra Zeneca, Beigene and Genentech-Roche. A.deF. is supported by grants from the U.S. Army Medical Research and Materiel Command, NHMRC, Cancer Institute NSW, Cancer Council New South Wales and AstraZeneca.